| Followers | 2518 |
| Posts | 143129 |
| Boards Moderated | 0 |
| Alias Born | 02/21/2011 |
Monday, February 22, 2016 8:41:48 AM
FDA Accepts Sanofi New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
~Real DD 0001 ~ 0010 Plays~
http://investorshub.advfn.com/boards/board.aspx?board_id=22489
~All posts are my opinion and are not recommendations to buy or sell~
Recent SNY News
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/07/2026 12:47:00 PM
- Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 • PR Newswire (US) • 05/06/2026 04:42:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/05/2026 10:06:57 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 10:04:08 AM
- Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) • GlobeNewswire Inc. • 04/22/2026 09:30:00 PM
- Sanofi devient la détentrice de l'autorisation de mise en marché de Nuvaxovid(MD) au Canada, élargissant ainsi les choix de vaccins contre la COVID-19 pour la population canadienne • PR Newswire (Canada) • 04/09/2026 02:00:00 PM
- Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians • PR Newswire (Canada) • 04/09/2026 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/31/2026 04:19:10 PM
- Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) • GlobeNewswire Inc. • 03/24/2026 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 02:40:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 05:26:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/03/2026 11:15:15 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2026 02:19:13 PM
- Sanofi announces leadership evolution in Specialty Care Business Unit • PR Newswire (US) • 02/17/2026 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/06/2026 03:09:38 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/05/2026 11:17:47 AM
- Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma • GlobeNewswire Inc. • 12/23/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/03/2025 04:30:33 PM
- Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) • GlobeNewswire Inc. • 11/25/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/18/2025 05:29:51 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2025 04:40:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/31/2025 05:48:30 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/29/2025 03:15:09 PM
- UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey • GlobeNewswire Inc. • 10/28/2025 12:47:31 AM
